Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F25%3A10491008" target="_blank" >RIV/00669806:_____/25:10491008 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00216208:11140/25:10491008
Výsledek na webu
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=je.w687o7r" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=je.w687o7r</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1080/1750743X.2025.2452145" target="_blank" >10.1080/1750743X.2025.2452145</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations
Popis výsledku v původním jazyce
BackgroundThe present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI).Materials and methodsWe performed a sub-analysis of a multicenter retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations.ResultsThree hundred and twenty-nine patients were enrolled, 244 males and 85 females. Median age was 65.5 years. The prognostic impact of the Hb/RDW ratio on PFS and OS was observed in the whole population examined. Hb/RDW ratio had a correlation with neutrophil-to-lymphocyte ratio (NLR), a blood inflammatory parameter.ConclusionHb/RDW ratio is a new inflammatory prognostic factor, easy to use in daily clinical practice. Prognostic factors are crucial to improve counseling of patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. Our goal is to explore the role of Hemoglobin to RDW ratio in predicting progression-free survival and overall survival.
Název v anglickém jazyce
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations
Popis výsledku anglicky
BackgroundThe present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI).Materials and methodsWe performed a sub-analysis of a multicenter retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations.ResultsThree hundred and twenty-nine patients were enrolled, 244 males and 85 females. Median age was 65.5 years. The prognostic impact of the Hb/RDW ratio on PFS and OS was observed in the whole population examined. Hb/RDW ratio had a correlation with neutrophil-to-lymphocyte ratio (NLR), a blood inflammatory parameter.ConclusionHb/RDW ratio is a new inflammatory prognostic factor, easy to use in daily clinical practice. Prognostic factors are crucial to improve counseling of patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. Our goal is to explore the role of Hemoglobin to RDW ratio in predicting progression-free survival and overall survival.
Klasifikace
Druh
J<sub>imp</sub> - Článek v periodiku v databázi Web of Science
CEP obor
—
OECD FORD obor
30204 - Oncology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2025
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Immunotherapy
ISSN
1750-743X
e-ISSN
1750-7448
Svazek periodika
17
Číslo periodika v rámci svazku
1
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
11
Strana od-do
25-35
Kód UT WoS článku
001400486100001
EID výsledku v databázi Scopus
2-s2.0-85215518337